Osimertinib has demonstrated efficacy for patients with epidermal growth factor receptor (EGFR) T790M positive non-small cell lung cancer (NSCLC) in clinical trials. However, data on the effectiveness of osimertinib in real-world settings remain scarce.
Nivolumab is current standard of care for patients with pretreated advanced non-small cell lung cancer (NSCLC). The patients' and physicians' experience of using nivolumab in real-world clinical practice in Taiwan is unknown. We aimed to evaluate the efficacy and safety of nivolumab therapy in Taiwan.